Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Phase III study of sparsentan in FSGS achieves interim proteinuria endpoint

Feb. 2, 2021

Zymso approved in Japan for interstitial cystitis

Jan. 26, 2021

FDA approves Lupkynis oral therapy for lupus nephritis

Jan. 25, 2021

New chymase inhibitors patented by Medshine Discovery

Jan. 22, 2021

New causal gene for chronic kidney disease

Jan. 18, 2021

BioMarin Pharmaceutical identifies HAO1 inhibitors

Jan. 14, 2021

Finerenone lowers risk of CKD progression and cardiovascular events in CKD with type 2 diabetes

Jan. 13, 2021

FDA allows Cure's IND for CUREfilm Blue

Jan. 7, 2021

Kyowa Kirin opens phase III study of bardoxolone methyl for ADPKD in Japan

Jan. 7, 2021

RCAN1 is involved in tubulointerstitial fibrosis progression by regulating mitochondrial quality

Dec. 30, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.